Results 121 to 130 of about 11,492 (188)

CHO Cell Line Selection through Multi‐Criteria Analysis Reveals Critical Impact of Gas Overlay

open access: yesBiotechnology Journal, Volume 21, Issue 3, March 2026.
Graphical Abstract and Lay Summary Multivariate data analysis (MVDA) integrated productivity, growth, stability, and metabolism to rank monoclonal antibody producing CHO clones. From 24 candidates cultivated in well plates, eight were selected for bioreactor experiments. Bioreactor cultures without air overlay had increased pCO2 and unexpectedly better
Jimmy Gaudreault   +13 more
wiley   +1 more source

Feasibility and Patient Experiences in a WhatsApp‐Based Educational Pilot for Spanish‐Speaking Adults With Chronic Spontaneous Urticaria

open access: yes
International Journal of Dermatology, EarlyView.
Elise Edwards   +5 more
wiley   +1 more source

A Link Between Allergy and Hematological Malignancies? Focus on Possible Mechanisms and the Potential Role of Biological Therapies

open access: yesClinical and Translational Allergy, Volume 16, Issue 3, March 2026.
ABSTRACT Immune dysregulation has been widely recognized in the international literature as an underlying condition for hematological malignancies and allergic disorders. This commonality has led researchers to study the potential association, positive or negative, between blood cancers and allergy, but the results remain unclear.
Stefania Isola   +5 more
wiley   +1 more source

Omalizumab in the management of patients with allergic (IgE-mediated) asthma

open access: yesJournal of Asthma and Allergy, 2009
Thomas SandströmDepartment of Respiratory Medicine and Allergy, University Hospital, Umeå, SwedenAbstract: Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma.
Thomas Sandström
doaj  

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

open access: yesJEADV Clinical Practice, Volume 5, Issue 1, Page 101-116, March 2026.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson   +12 more
wiley   +1 more source

Atopic Comorbidities Associated With Chronic Spontaneous Urticaria: A Case‐Control Analysis of the All of Us Research Program

open access: yesJEADV Clinical Practice, Volume 5, Issue 1, Page 194-197, March 2026.
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a mast cell‐driven condition defined by recurrent wheals and/or angioedema lasting over 6 weeks without an identifiable trigger. Though CSU is known to co‐occur with atopic diseases and share Th2‐dominant immunologic pathways, prior studies have not adequately addressed these relationships in ...
Julian A. Cortes   +4 more
wiley   +1 more source

A severe case of lipoatrophy due to human insulin and insulin analogs in a patient with diabetes: is an immunological mechanism involved? [PDF]

open access: yes, 2011
The precipitin technique has been used in insulin resistance and immunity studies since the 1940s [7]. In the case described, the technique proved, once again, to be a valid method for choosing the most appropriate insulin. However, whether or not an
Cabrera-Freitag, P. (P.)   +5 more
core  

Impact of Early Versus Delayed Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps

open access: yesOtolaryngology–Head and Neck Surgery, Volume 174, Issue 3, Page 671-677, March 2026.
Abstract Objective Previous studies have suggested a benefit to early functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis (CRS). With the approval of T2 biologics for CRS with nasal polyps (CRSwNP), it is important to re‐evaluate FESS timing in relation to T2 biologic utilization.
Radhika Duggal   +4 more
wiley   +1 more source

The role of omalizumab in the treatment of adults with severe allergic asthma

open access: yesZdravniški Vestnik, 2013
Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija.
Sabina Škrgat Kristan
doaj  

Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database

open access: yesRheumatology &Autoimmunity, Volume 6, Issue 1, Page 39-50, March 2026.
This observational study assessed the association between anti‐type 2 biologic agents and the occurrence of autoimmune diseases using a large real‐world claims database. Anti‐IL‐5 and anti‐IgE therapies were associated with an increased occurrence of autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE ...
Shoichiro Inokuchi
wiley   +1 more source

Home - About - Disclaimer - Privacy